Company intelligence / Profile preview

BioRg3 Innovations

Montreal, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

BioRg3 Innovations is a Canadian biotechnology company focused on developing therapeutic solutions for rare neuromuscular disorders, particularly Duchenne Muscular Dystrophy (DMD). The company leverages the anti-inflammatory and anti-fibrotic properties of Ginsenoside Rg3, a bioactive compound derived from Panax ginseng, to address muscle degeneration. Their lead program aims to provide a safer and more effective alternative or adjunct to current corticosteroid treatments by inhibiting the NF-kappaB pathway. BioRg3's research is supported by collaborations with academic institutions and Canadian research consortia to advance their candidates toward clinical validation.

Therapeutic areas: Rare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

CQDM

Beyond the preview

Go deeper on BioRg3 Innovations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioRg3 Innovations.

Explore the full profile